English to Chinese Medical Chemistry; Chem Sci/Eng

Step 3. In a Smith process vial (10-20 mL capacity) is added 3-iodo-1H-thieno[3,2-c]pyrazole-5-carboxylic acid (pyridin-2-ylmethyl)-amide [255 mg, 0.664 mmol, Intermediate (30)], 5-(tert-butyl-dimethyl-silanyloxymethyl)-1H-indole-2-boronic acid 1-carboxylic acid tert-butyl ester [404 mg, 0.997 mmol, Intermediate (8), prepared as described in Example 1-4 of International Patent Application Publication No. WO 02/32861], tetrakis(triphenylphosphine)palladium(0) (77mg, 0.0666 mmol), potassium carbonate (2M aqueous, 1 mL) and toluene/ethanol (6:3 mL).

步骤3. 在一个史密斯反应瓶(容量10 - 20 mL)中加入3-碘代-1H-噻吩併[3,2–c]吡唑-5-羧酸(吡啶-2-基甲基)-胺[ 255 mg, 0.664 mmol,中间体( 30)]、5-(叔丁基-二甲基-硅烷氧基甲基)-1H-吲哚-2-硼酸1-羧酸叔丁基酯[ 404 mg, 0.997 mmol,中间体( 8),如国际专利申请公布号WO 02/32861例1 - 4所述], tetrakis (三苯基膦)钯( 0) ( 77mg, 0.0666 mmol),碳酸钾( 2M水溶液, 1 mL)与甲苯/乙醇( 6:3 mL)。

tetrakis 是什么？